Calamos Advisors
UTHR icon

Calamos Advisors’s United Therapeutics UTHR Stock Holding History

Calamos Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,984
Closed -$1.66M – 1209
2022
Q4 		$1.66M Buy
5,984
+3,037
+103% +$767K 0.01% 816
2022
Q3 		$617K Buy
2,947
+721
+32% +$161K ﹤0.01% 998
2022
Q2 		$525K Buy
+2,226
New +$453K ﹤0.01% 1066

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Calamos Advisors's UTHR Position: Q1 2023 in Review

Calamos Advisors sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 5,984 shares — an estimated $1.66M sold.

Calamos Advisors first reported a position in UTHR in Q2 2022 and held it in 3 quarters. The position peaked at $1.66M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Calamos Advisors reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Calamos Advisors sold 5,984 United Therapeutics shares in Q1 2023, an estimated $1.66M.
  • Calamos Advisors first reported a position in United Therapeutics in Q2 2022 and held it in 3 quarters.
  • Calamos Advisors's United Therapeutics position peaked at $1.66M in Q4 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.